A Study of angiogenesis in human endometrial denocarcinoma, and premalignant endometrial lesions: A comparative clinic pathological study

  • Maha Shakir Hassan Thi-Qar.College of medicine.Thi-Qar.Iraq


Background: The development of new blood vessels is essential to embryonic growth and throughout life for physiological repair processes. Tumors cannot enlarge beyond 1-2 mm in diameter or thickness unless they are vascularized. Angiogenesis is an essential step in growth of primary tumor and for distant metastasis. MVD (Microvessel Density)  is one of the important measurement to asses angiogenesis.  Aim: The aims of this study are to asses the micro vessel density (MVD)  of endometrium using two markers which are (CD31 and CD34),to investigate the relationship between the degree of angiogenesis and clinicopathological variants,  to determine its usefulness in histopathological practice, and to compare between the two markers. Materials and methods: This retrospective study includes formalin fixed, paraffin embedded tissue sections from patients underwent different gynecological diagnostic and therapeutic procedures. These samples were taken from the hospitals in the period between August 2005 and January 2007. forty nine cases were studied; 10 were normal functional endometrium; 21 hyperplasia, and 18 were diagnosed as endometrial carcinoma. Five slides for each case was done, one  slide was stained with Hematoxylin and eosin (H&E), and re-examined to confirm the diagnosis, and the other four were stained immunohistochemically for monoclonal antibodies CD31 and CD34 (two slides for each one). Results: This study showed that MVD was correlated with benign and malignant endometrial lesions. The mean MVD for normal functional endometrium cases was as follows: 53.9 using CD34 stain, and 47.5 using CD31 stain for secretory  endometrium, and 32.2 using CD34 and 30.1 using CD31 for the proliferative type. The mean MVD for hyperplastic endometrium was found to be: 63.2,45.8 (by CD34, and CD31 respectively) for cystic; 75.1 and 69.7(by CD34, and CD31 respectively) for adenomatous, and 78.4,73.2 (by CD34, and CD31 respectively) for atypical endometrial hyperplasia. Regarding the malignant cases, the mean MVD was: 87.43, 70.22 for well differentiated adenocarcinoma; for moderately differentiated cases they were 102.6, 88.35; and 114.8, 102.7 for poorly differentiated cases (by CD34, and CD31 respectively). The results of mean MVD using CD34 is significantly higher than that obtained by using CD31 for both benign and malignant cases (the p values are 0.0412, and 0.0327 respectively). This study showed that MVD is significantly correlated with the benign and malignant endometrial lesions, but no significant statistical correlation between age and the MVD of the malignant cases. Conclusion: MVD is an important parameter to asses angiogenesis in functional, hyperplasic and malignant endometrium, and it was found to be higher in malignant cases than benign ones. Significantly higher results obtain for CD34 in comparison with CD31for both benign and malignant cases.


- Hendrickson MR and Kempson RL. The differential diagnosis of endometrial adenocarcinoma: Some view points concerning a common diagnostic problem. Pathology 1980; 12: 35-61.

- Mutter GL, Wada H, Faquin WC and Enomoto I. K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial

carcinogensis. Mol Pathol. 1999 Oct; 52(5):257-62.

- Kraus FT. High risk and premalignant lesions of the endometrium. Am J Surg Pathol 1985; 9(suppl): 3 1-40.

- Parkin DM, Pisani P and Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancerl993 Dec; 55(6):891-903.

- Iraqi Cancer Registry (ICR) issued for the years between 1998 and 2002.

- Gusberg SB and Milano C. Detection of endometrial carcinoma and its precursors. Cancer. 1981 Mar; 47(5 Suppl):1173-5.

- Beckner ME, Mon T and Silverberg SG. Endometrial canrcinoma: Non-tumor factors in prognosis. Int J Gynecol Pathol. 1985; 4(2): 131-45.

- Deligdisch L. Hormonal pathology of the endometrium. Med pathol 2000; 13(3): 285-94.

- Rosai J. Special techniques in surgical pathology. Volume 1, chapter 3: pp.37-156.

- Zaino RJ, Kurman RJ, Diana KL and Morrow CP. Pathologic models to predict outcome for women with endornetrial adenocarcinoma: The importance of the distinction between surgical stage and clinical stage--a Gynecologic Oncology Group study. Cancer. 1996 Mar; 77(6):l 115-21.

- Kurman RJ, Kaminski PF and Norris HJ. The behavior of endornetrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer. 1985 Jul; 56(2):403-12.

- Brem S, Cotran R and Folkman J. Tumor angiogenesis: A quantitative method for histological grading. J Nati Cancer Inst. 1972 Feb; 48(2):347-56. Breman ML and McHale MT. Uterus, chapter 57, pp.951-66. In Kaskell CM. Cancer treatment. Fifth edition, 2001.

- Weidner N, Semple JP, Welch WR and Folkman J. El: tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991 Jan; 324(1): 1-8.

- Laitakari J, Harrison D and Stenback F. Morphometric characteristics of cell proliferation and p53 expression in development of experimentally induced respiratoiy tumors. Analyt Quant Cytol Histol 2001; 23, 273-86.

- Lohmann CM, Fields AC, Schiller A et al. Quantitation of angiogenesis by measuring CD3 1 and factor VIII visually and by image cytometry in renal cell carcinoma_prognostic significance. J Urol Pathol 1999; 11: 101-12.

- Fox SB. Microscopic assessment of angiogenesis in tumors, chapter2. Human press 2001;pp.29-49.

- Vesalainon S, Lipponen P, Taija M, Alhava E and Syrjanen K. Tumor vascularity and basement membrane structure as prognostic factors in Ti -2M0 prostatic adenocarcinoma. Anticancer Res. 1994 Mar-Apr; 1 4(2B):709- 14.

- Rosai J. Rosai and Ackerman’s surgical pathology. Appendix C: Staging of cancer: pp.28O1-29.Elsevier.Ninth edition, 2004c.

- Kaku T, Karnura T, Kinukawa N, Kobayashi H, Sakal K, Tsuruchi N, Saito T, Kawauchi S, Tsuneyoshi M and Nakano H. Angiogenesis in endometrial carcinoma. Cancer. 1997 Aug; 80(4):741-7.

- Wagatsuma 5, Konno R, Sato S and Yajima A. Tumor angiogenesis, hepatocyte growth factor and c-met expression iii endometrial carcinoma. Cancer.

Feb; 82(3):520-30.

- Ling V, Liixenberg D, Wang J, Nickbarg E, Leenen PJ, Neben S and Kobayashi M. Structural identification of the hematopoietic progenitor antigen ER-MP 12 as the vascular endothelial adhesion molecule PECAM- 1 (CD3 1). Eur J Immunol. 1997 Feb; 27(2):509-14.

- Chu JS, Huang CS and Chang KJ. The prognostic significance of tumor angiogenesis in Taiwanese patients with invasive ductal breast carcinomas. Cancer Lett. 1998 Dec; 134(1):7-14.

- Al-Obaidi AB. IFN-y versus IL-0 in situ expression and immunohistochemistry analysis of VCAM- I, PECAM- 1 and HCMV in recurrent spontaneous abortion. A thesis submitted to college of medicine — Al-Nahrain University in partial fulfillment of the requirements for the degree of Master of Science in medical microbiology. 2005.

- Greaves MF, Brown J, Molgaard HV, Spurr NK, Robertson D, Delia D and Sutherland DR. Molecular features of CD34: a hematopoietic progenitor cell- associated molecule. Leukemia. 1992; 6 Suppl 1:31-6.

- Katz FE, Tindle R, Sutherland DR and Greaves MF. Identification of a glycoprotien associated with hemopoitic progenitor cells. Leuk Res.

; 9(2):191-8.

- Brown J, Greaves MF and Molgard HV. The gene encoding the stem cell antigen CD34 is conserved in mouse and expressed in hemopoietic progenitor cell lines, brain, and embryonic fibroblasts. IntImmunol. 1991 Feb; 3(2):175-84.

- Schoell WM, Pieber D, Reich 0, Lahousen M, Janicek M, Guecer F and Ninrer R. Tumor angiogenesis as a prognostic factor in ovarian carcinoma. Cancer. 1997 Dcc; 80(12):2257-62.

- Hansen S, Graban BA, Sorensen FB, Bak M, Vach W and Rose C. Vascular grading of angiogenesis: Prognostic significance in breast cancer. Br J Cancer. 2000 Jan; 82:339-47.

- PoOn RT, Ng TO, Lau C, Yn WC, Yang ZF, Fan ST and Wong J. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: A prospective study. J Clin Oncol. 2002 Apr; 20(7):l775-85.

- Van Hoef MEHM, Knox WE, Dhesi 55, HoweJi A, Schor AM. Assessment of tumor vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 1993; 29A: 1141-5.

- Daboagh SR. Assessment of AgNOR in normal, hyperplastic and endometrial adenocarcinoma. A thesis submitted to the scientific council of pathology in partial fulfillment of the requirement for the degree of followship of Iraqi commission for medical specialization in pathology. 2003.

- Sherman Al and Brown S. The precursors of endometrial carcinoma. Am J Obstet Gynecol 1979; 135: 947-56.

-Fox SB. Microscopic assessment of angiogenesis in tumors, chapter 2. In Murray JC. Angiogenesis protocols. Humana press 2001; pp.29-46.

- Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002 Dec; 29(6 Suppl16):15-8.

- Slitonen SM, Haapasalo HK, Rantala IS, Helm HJ and Isola JJ. Comparision of different immunohistochemical methods in the assessment of angiogenesis:

Lack of prognostic value in group of 77 selected node-negative breast carcinoma. Mod Pathol 1995; 8: 745-52.

- Fox SB. Microscopic assessment of angiogenesis in tumors, chapter3. Human press 2001;pp.29-49.

- Ozuvsal 5, Bilgin T, Ozan H, Kara HF, Ozturk H and Ercani. Angiogenesis endometrial carcinoma. Correlation with survival and clinicopathologic risk Factors. Gynecologic and Obstetric Investigation 2003; 55(3): 173-7.

- Erdem 0, Erdem M, Dursun A, Akyol G and Erdem A. Angiogenesis, p53 and bcl-2 expression as prognostic indicator in endometrial cancer: Comparision with traditional clinicopathologic variables. Int J Gynecol Pathol 2003 Jul; 22(3): 254-60.

- Salvesen HB, Iversen OE and Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53 and p21 expression: A population-based endometrial carcinoma study. J Clin Oncol. 1999 May; 17(5):l382-90.

In Rosai and Ackerman’s surgical pathology. Elsevier. Ninth edition, 2004a.

-Fujiwaki R, Iida K, Kanasaki H, Ozaki T, Hata K and Miyazaki K.

Cyclooxygenase-2 expression in endometrial cancer. Correlation with microvessel count and expression of vascular endothelial growth factor and thymidin phosphorylase. Human Pathol 2002 Feb; 33(2): 213-8.

- Bai X and Mi R. Expression of basic fibroblast growth factor and microvessel density in endornetrial carcinoma. Zhonghua Fu Chan Ke Za Zhi 2000 Jun; 35(6): 348-51.

- AL-Qureishi LF. The prognostic role of CD34 in the angiogenesis of endometriall carcinoma. A thesis submitted to the scientific council of pathology as a partial fulfillment of the requirement for the degree of Board inpathology. 2005